Cargando…
Chromoendoscopy in Combination with Random Biopsies for Patients with Pathogenic CDH1 Mutations Undergoing Endoscopic Surveillance
OBJECTIVES: Germline mutations in the CDH1-gene are identified as the cause of 30–40% of cases of hereditary diffuse gastric cancer, an autosomal-dominant inherited cancer predisposition syndrome. Given this high risk of developing diffuse gastric cancer, carriers of a pathogenic CDH1 germline mutat...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435617/ https://www.ncbi.nlm.nih.gov/pubmed/35499650 http://dx.doi.org/10.1007/s12029-022-00831-1 |
_version_ | 1785092142375370752 |
---|---|
author | Ruf, Benjamin Roggia, Cristiana Schroeder, Christopher Mattern, Sven Fend, Falko Klag, Thomas Götz, Martin |
author_facet | Ruf, Benjamin Roggia, Cristiana Schroeder, Christopher Mattern, Sven Fend, Falko Klag, Thomas Götz, Martin |
author_sort | Ruf, Benjamin |
collection | PubMed |
description | OBJECTIVES: Germline mutations in the CDH1-gene are identified as the cause of 30–40% of cases of hereditary diffuse gastric cancer, an autosomal-dominant inherited cancer predisposition syndrome. Given this high risk of developing diffuse gastric cancer, carriers of a pathogenic CDH1 germline mutation are advised to undergo prophylactic gastrectomy. For patients preferring conservative management, endoscopic surveillance is recommended. The detection of diffuse gastric cancer using white light endoscopy, however, remains challenging. METHODS: Patients with pathogenic CDH1 mutation underwent (chromo)endoscopic surveillance or endoscopy prior to surgery. Biopsies were taken at suspicious sites identified by chromoendoscopy. In addition, endoscopically normal areas were assessed with mapping biopsies. Detection rates from endoscopic biopsies (mapping vs. targeted) and gastrectomy specimen were then compared. RESULT: Between 11/2015 and 12/2020, ten patients from four families with a known CDH1 germline mutation had a total of n = 24 endoscopies with n = 518 total biopsies being examined. Three patients were diagnosed with GC during the study period. These patients all had suspicious chromoendoscopic lesions (= detection rate 100%). In two of three patients who had suspicious chromoendoscopic lesions, signet cell carcinoma was also detected in mapping biopsies and multiple additional cancer foci were identified in the gastrectomy specimen. CONCLUSION: Chromoendoscopy facilitated detection of gastric carcinoma foci in CDH1 mutation carriers. Chromoendoscopy identified all patients with gastric cancer, but not all cancer foci present in these patients. We conclude that for patients opting against prophylactic total gastrectomy, the addition of chromoendoscopy to white light could be used to enhance diagnostic reliability of endoscopic surveillance. |
format | Online Article Text |
id | pubmed-10435617 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-104356172023-08-19 Chromoendoscopy in Combination with Random Biopsies for Patients with Pathogenic CDH1 Mutations Undergoing Endoscopic Surveillance Ruf, Benjamin Roggia, Cristiana Schroeder, Christopher Mattern, Sven Fend, Falko Klag, Thomas Götz, Martin J Gastrointest Cancer Original Research OBJECTIVES: Germline mutations in the CDH1-gene are identified as the cause of 30–40% of cases of hereditary diffuse gastric cancer, an autosomal-dominant inherited cancer predisposition syndrome. Given this high risk of developing diffuse gastric cancer, carriers of a pathogenic CDH1 germline mutation are advised to undergo prophylactic gastrectomy. For patients preferring conservative management, endoscopic surveillance is recommended. The detection of diffuse gastric cancer using white light endoscopy, however, remains challenging. METHODS: Patients with pathogenic CDH1 mutation underwent (chromo)endoscopic surveillance or endoscopy prior to surgery. Biopsies were taken at suspicious sites identified by chromoendoscopy. In addition, endoscopically normal areas were assessed with mapping biopsies. Detection rates from endoscopic biopsies (mapping vs. targeted) and gastrectomy specimen were then compared. RESULT: Between 11/2015 and 12/2020, ten patients from four families with a known CDH1 germline mutation had a total of n = 24 endoscopies with n = 518 total biopsies being examined. Three patients were diagnosed with GC during the study period. These patients all had suspicious chromoendoscopic lesions (= detection rate 100%). In two of three patients who had suspicious chromoendoscopic lesions, signet cell carcinoma was also detected in mapping biopsies and multiple additional cancer foci were identified in the gastrectomy specimen. CONCLUSION: Chromoendoscopy facilitated detection of gastric carcinoma foci in CDH1 mutation carriers. Chromoendoscopy identified all patients with gastric cancer, but not all cancer foci present in these patients. We conclude that for patients opting against prophylactic total gastrectomy, the addition of chromoendoscopy to white light could be used to enhance diagnostic reliability of endoscopic surveillance. Springer US 2022-05-02 2023 /pmc/articles/PMC10435617/ /pubmed/35499650 http://dx.doi.org/10.1007/s12029-022-00831-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Research Ruf, Benjamin Roggia, Cristiana Schroeder, Christopher Mattern, Sven Fend, Falko Klag, Thomas Götz, Martin Chromoendoscopy in Combination with Random Biopsies for Patients with Pathogenic CDH1 Mutations Undergoing Endoscopic Surveillance |
title | Chromoendoscopy in Combination with Random Biopsies for Patients with Pathogenic CDH1 Mutations Undergoing Endoscopic Surveillance |
title_full | Chromoendoscopy in Combination with Random Biopsies for Patients with Pathogenic CDH1 Mutations Undergoing Endoscopic Surveillance |
title_fullStr | Chromoendoscopy in Combination with Random Biopsies for Patients with Pathogenic CDH1 Mutations Undergoing Endoscopic Surveillance |
title_full_unstemmed | Chromoendoscopy in Combination with Random Biopsies for Patients with Pathogenic CDH1 Mutations Undergoing Endoscopic Surveillance |
title_short | Chromoendoscopy in Combination with Random Biopsies for Patients with Pathogenic CDH1 Mutations Undergoing Endoscopic Surveillance |
title_sort | chromoendoscopy in combination with random biopsies for patients with pathogenic cdh1 mutations undergoing endoscopic surveillance |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435617/ https://www.ncbi.nlm.nih.gov/pubmed/35499650 http://dx.doi.org/10.1007/s12029-022-00831-1 |
work_keys_str_mv | AT rufbenjamin chromoendoscopyincombinationwithrandombiopsiesforpatientswithpathogeniccdh1mutationsundergoingendoscopicsurveillance AT roggiacristiana chromoendoscopyincombinationwithrandombiopsiesforpatientswithpathogeniccdh1mutationsundergoingendoscopicsurveillance AT schroederchristopher chromoendoscopyincombinationwithrandombiopsiesforpatientswithpathogeniccdh1mutationsundergoingendoscopicsurveillance AT matternsven chromoendoscopyincombinationwithrandombiopsiesforpatientswithpathogeniccdh1mutationsundergoingendoscopicsurveillance AT fendfalko chromoendoscopyincombinationwithrandombiopsiesforpatientswithpathogeniccdh1mutationsundergoingendoscopicsurveillance AT klagthomas chromoendoscopyincombinationwithrandombiopsiesforpatientswithpathogeniccdh1mutationsundergoingendoscopicsurveillance AT gotzmartin chromoendoscopyincombinationwithrandombiopsiesforpatientswithpathogeniccdh1mutationsundergoingendoscopicsurveillance |